BIOCRYST PHARMACEUTICALS INC cotiza a 8.07 USD y tiene una capitalización bursátil de $2.1B. En los últimos 12 meses ha facturado $941M con un margen de flujo de caja libre del 39.4%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RA…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $0.35 | $0.14 | $0.21 |
| Estimado | $0.12 | $0.24 | $0.11 | $0.07 |
| Sorpresa | — | +45.8% | +27.3% | +200.0% |
| Métrica | BCRX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 97.8% | 57.0% | +40.8% |
| Operating Margin | 39.0% | -38.6% | +77.6% |
| Net Margin | 30.2% | -33.6% | +63.7% |
| FCF Margin | 39.4% | -13.9% | +53.3% |
| ROE | — | -40.4% | — |
| ROA | 51.3% | -32.0% | +83.3% |
| Current Ratio | 2.06 | 2.84 | -0.78 |
| Debt / Equity | 0.00 | 0.28 | -0.28 |